Number of participants with treatment emergent adverse events (TEAE) of special interest;Area under the concentration vs. time curve (AUC0-last), AUC0-∞);Time of maximum serum concentration (Tmax);Minimum observed serum concentration (Cmin);Maximum observed serum concentration (Cmax);Number of participants with treatment-emergent adverse events (TEAE);Terminal half-life (T1/2);Systemic clearance (CL);Steady-state volume of distribution (Vss);Number of participants with treatment emergent serious adverse events (TESAEs)

Number of participants with treatment emergent adverse events (TEAE) of special interest;Area under the concentration vs. time curve (AUC0-last), AUC0-∞);Time of maximum serum concentration (Tmax);Minimum observed serum concentration (Cmin);Maximum observed serum concentration (Cmax);Number of participants with treatment-emergent adverse events (TEAE);Terminal half-life (T1/2);Systemic clearance (CL);Steady-state volume of distribution (Vss);Number of participants with treatment emergent serious adverse events (TESAEs)